openPR Logo
Press release

New Investigational Drug TB006 FDA - Approved For Compassionate Use

04-21-2025 06:28 PM CET | Health & Medicine

Press release from: Getnews

/ PR Agency: Brand Featured
New Investigational Drug TB006 FDA - Approved For Compassionate

Naples, FL - April 21, 2025 - TB006, a new investigational drug, has been approved by the US Food and Drug Administration (FDA) for compassionate use and is currently being evaluated in a clinical trial for Alzheimer's disease. The FDA's compassionate use designation allows patients with serious or life-threatening conditions to access investigational treatments when no satisfactory alternatives are available.

TB006 is currently undergoing clinical trials to assess its safety and potential effects on inflammation and cognitive function in individuals diagnosed with Alzheimer's disease. According to clinical investigators involved in early-stage research, the drug has been administered to over 300 patients to date, with no adverse side effects reported.

Preliminary data from a placebo-controlled trial [https://alzheimersnewstoday.com/news/signs-alzheimers-reversed-eased-after-3-months-tb006/] suggested that:

*
Nearly half of those who took TB006 for at least 3 months showed signs of disease reversal and cognitive improvement

*
Those who took TB006 had lower levels of inflammation. Reducing inflammation is very important because inflammation is a major cause of Alzheimer's disease.

These findings are currently being further investigated through ongoing clinical studies. With Alzheimer's disease on the rise, this is very exciting news for those over age 65 and those with a history of dementia in their family.

Among the clinical sites authorized to provide TB006 under compassionate use is Brain Power Clinics, located in West Palm Beach, Florida. The clinic is led by Dr. Joshua Helman, a Harvard-trained physician with over a decade of experience focused on integrative approaches to cognitive decline. Known to patients as Dr. Josh, he currently administers TB006 under FDA protocols as part of a broader, individualized care model.

Dr. Helman works in partnership with Dr. Robert Love, Ph.D., a neuroscientist recognized for his contributions to the field of Alzheimer's prevention and brain health. Together, the team at Brain Power Clinics offers a multidisciplinary approach that combines investigational therapies like TB006 with behavioral coaching and lifestyle interventions designed to support cognitive function.

Participation in the compassionate use program is limited to individuals who meet specific eligibility criteria, which include age and diagnosis parameters in accordance with FDA and clinical trial guidelines.

To learn more about working with Dr. Josh in his medical clinic, please text "Memory" to 561-725-3319 or visit www.BrainPowerClinics.com [http://www.brainpowerclinics.com/].

Disclaimer: The expert opinions presented in this PR/Story are based on the extensive experience and knowledge of the source company. These views do not necessarily reflect the opinions of the news distribution company and its distribution partners. There is no offer to sell, no solicitation of an offer to buy, and no recommendation of any medical treatment, product, or service in this article. Moreover, nothing contained in this should be construed as medical advice or a recommendation to start, stop, or change any medical treatment or medication. It is your responsibility to determine whether any medical treatment, product, or service is appropriate for you based on your health objectives, medical condition, and risk tolerance. Consult your healthcare provider regarding your specific medical situation. The news distribution company and its distribution partners do not endorse or guarantee the accuracy, completeness, or reliability of the information shared by the guest. Viewers are encouraged to consult with their own healthcare professionals or conduct their own research when making decisions related to medical topics. The source company is the one issuing this release. Please contact them directly for further information.
Media Contact
Company Name: Brain Power Clinics
Contact Person: Robert Love
Email: Send Email [http://www.universalpressrelease.com/?pr=new-investigational-drug-tb006-fda-approved-for-compassionate-use]
Phone: 305-209-0853
Country: United States
Website: http://www.BrainPowerClinics.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release New Investigational Drug TB006 FDA - Approved For Compassionate Use here

News-ID: 3980033 • Views:

More Releases from Getnews

360WiSE Registered Launches New Era in Media & Brand Authority Engineering
360WiSE Registered Launches New Era in Media & Brand Authority Engineering
Image: https://www.globalnewslines.com/uploads/2025/09/1759247651.jpg Robert Alexander, CEO of 360WiSE Registered , highlights the company's mission to blend Smart TV distribution, press placement, and AI-driven authority engineering for legacy-driven brands. 360WiSE unveils integrated Smart TV, press, and AI tools to help brands build lasting authority and cultural impact. Miami, FL - Sep 30, 2025 - 360WiSE Registered , a pioneering force in independent media, brand marketing, and press syndication, today announced its next chapter of strategic
Best GLP-1 App for 2025: MeAgain Takes Top Position
Best GLP-1 App for 2025: MeAgain Takes Top Position
MeAgain has been recognized as the #1 GLP-1 app in the market, supporting users on medications like Zepbound, Mounjaro, Wegovy, Ozempic, and compounded versions such as Tirzepatide and Semaglutide. The platform offers comprehensive tracking including injection reminders, side effect management, nutrition tracking, and an AI coach for personalized support. Users praise its all-in-one approach: "I used to juggle 4 different apps. This one app now does it all," says user
Springville Freedom Credit Union Expands Auto and RV Loan Services to Better Serve the Community
Springville Freedom Credit Union Expands Auto and RV Loan Services to Better Ser …
Image: https://www.globalnewslines.com/uploads/2025/09/1759164728.jpg Springville Freedom Credit Union has announced expanded offerings designed to make vehicle ownership more accessible and affordable for the community. With a commitment to providing flexible financial solutions, the credit union now offers specialized loan programs to meet the growing demand for reliable transportation and recreational financing. One of the newest offerings includes a New Car Loan Springville [https://www.google.com/maps?cid=7057362679886001310] program, designed to help individuals drive away in the latest models
PushAds.net Launches New AI-Driven Toolkit to Boost Ad Campaign ROI and Targeting Precision
PushAds.net Launches New AI-Driven Toolkit to Boost Ad Campaign ROI and Targetin …
Image: https://www.globalnewslines.com/uploads/2025/09/1758887006.jpg Image by FatAds Platform enhances Smart Bidding, adds Granular Targeting and In-Page Push to address demands for quality and efficiency in push traffic. LIMASSOL, Cyprus - PushAds.net, a rapidly expanding push notification advertising platform, today announced a significant upgrade to its technological infrastructure. The update introduces a new suite of targeting and optimization tools designed to deliver higher Click-Through Rates (CTR) and a superior Return on Investment (ROI) for marketers, affiliates,

All 5 Releases


More Releases for TB006

Alzheimer's Disease Clinical Trials 2025: EMA, PDMA, FDA Approvals, Treatment Ma …
(Albany, USA) DelveInsight's 'Alzheimer's disease Pipeline Insight 2025' report provides comprehensive global coverage of pipeline Alzheimer's disease therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Alzheimer's disease pipeline domain. For Alzheimer's disease emerging drugs, the Alzheimer's disease pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration,
05-06-2025 | Health & Medicine
Getnews
FDA Grants Compassionate Use of Alzheimer's Drug TB006, Now Accessible in Southe …
West Palm Beach, FL - May 5, 2025 - Brain Power Clinics, a Florida-based healthcare provider specializing in cognitive conditions, announces the availability of TB006 for compassionate use in the treatment of Alzheimer's disease. The new drug, currently in clinical trials, has shown promising early results in addressing memory loss and other symptoms associated with dementia. Promising New Treatment for Alzheimer's Disease TB006, now available through Brain Power Clinics in Southern Florida,
Alzheimer's Disease Drug Development Pipeline: 2025-A Surge in Innovation as 110 …
DelveInsight unveils its latest report, highlighting the evolving landscape of the Alzheimer's disease pipeline, with over 110 pharma and biotech companies like BioVie, Novo Nordisk, Alector, Longeveron, Cognition Therapeutics, TrueBinding, VT BIO, Luye Pharma Group, Lexeo Therapeutics, Merck Sharp & Dohme LLC, and Regeneration Biomedical, advancing novel Alzheimer's disease drugs set to reshape the Alzheimer's disease market. The fight against Alzheimer's disease is gaining momentum. In its newly released "Alzheimer's disease
Dementia Market 2032: Epidemiology Data, Pipeline Breakthroughs, Regulatory Land …
The Dementia Market size was valued approximately USD 21 million in 2021 and the report offers an in-depth understanding of the Dementia, historical and forecasted epidemiology as well as the Dementia market trends in the 7MM. DelveInsight's "Dementia Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Dementia, historical and forecasted epidemiology as well as the Dementia market trends in the United States, EU4 (Germany, Spain, Italy,
Ischemic Stroke Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Ischemic Stroke Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Ischemic Stroke pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Ischemic Stroke Pipeline Report • Over 50+ Ischemic Stroke
Alzheimer's Disease Drug Pipeline Analysis: FDA Approvals, Clinical Trials, Ther …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Alzheimer's disease pipeline constitutes 150+ key companies continuously working towards developing 160+ Alzheimer's disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Alzheimer's disease Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alzheimer's disease Market. The Alzheimer's disease Pipeline report